Because stand-alone pharmacokinetic (PK) studies are usually designed to focus on intrinsic and extrinsic factors that have a high potential to affect drug exposure, they leave other possible interactions unstudied; population PK (popPK) analysis allows for an assessment of multiple factors that are not otherwise evaluated in healthy volunteers and allows for a larger number of individuals to be included.
HLX01, a biosimilar rituximab approved by China’s National Medicinal Products Administration in February of this year, is China’s first biosimilar product to be approved under national guidelines that were set forth in 2015. The biosimilar was approved to treat lymphoma, and it was simultaneously developed as a novel product for the treatment of rheumatoid arthritis (RA), as the reference rituximab was not approved to treat RA in China, so no extrapolation for the indication could be granted.
The biosimilar is currently in phase 3 clinical development for RA, and during the European Society for Medical Oncology Asia Congress 2019, held last week in Singapore, researchers reported on their development of a population (pop) pharmacokinetic (PK) model that used PK data from the biosimilar and its reference in patients with RA and employed validation from patients with diffuse large B-cell lymphoma (DLBCL).
Because stand-alone PK studies are usually designed to focus on intrinsic and extrinsic factors that have a high potential to affect drug exposure, they leave other possible interactions unstudied; popPK analysis allows for an assessment of multiple factors that are not otherwise evaluated in healthy volunteers and allows for a larger number of individuals to be included.
The popPK model of the biosimilar and the EU-licensed reference from the study in 196 patients with RA had a serum sample number of 4289. It was developed with a nonlinear mixed-effect modeling using a first-order estimation with interaction method. PK and pharmacodynamic relationships were characterized using covariates including demographics and medical history, and these were examined using forward addition and backward elimination. The final model was validated using PK samples from the biosimilar and China-licensed reference rituximab from a study in 110 patients with DLBCL.
Using the model, the estimated clearance (CL), central volume (Vc), peripheral compartment volume, and clearance-of-distribution from the central to the peripheral compartment were 27.32%, 16.56%, 21.61%, and 40.79%, respectively. Correlation between CL and Vc was 0.02239.
The observed concentrations and simulations-based 95% CIs for the corresponding model successfully predicted all subjects in the data set, demonstrating PK similarity of the biosimilar and the reference in patients with RA and DLBCL, and no significant difference in area under the curve from zero to infinity was observed between the products.
According to the authors, the results of the model provide further evidence of the PK similarity of the biosimilar and its reference in both patients with RA and DLBCL.
Reference
Shi Y, Quin Y, Zhao S, et al. A population pharmacokinetic model: assessment of pharmacokinetic similarity of HLX01 and rituximab in diffuse large B-cell lymphoma. Presented at: European Society for Medical Oncology Asia Congress 2019; November 22-24, 2019; Singapore.
Eye on Pharma: Henlius, Organon Updates; Meitheal Portfolio Expansion; Celltrion Zymfentra Data
November 5th 2024Henlius and Organon’s pertuzumab biosimilar met phase 3 goals; Meitheal expanded its US biosimilars; Celltrion’s subcutaneous infliximab (Zymfentra) showed monotherapy could be as effective as combination therapy for inflammatory bowel disease.
Biosimilars Development Roundup for October 2024—Podcast Edition
November 3rd 2024On this episode of Not So Different, we discuss the GRx+Biosims conference, which included discussions on data transparency, artificial intelligence (AI), and collaboration to enhance the global supply chain for biosimilars and generic drugs, as well as the evolving requirements for biosimilar devices.
Panelists Stress Stakeholder Education to Build Confidence in Biosimilars
October 31st 2024By expanding educational initiatives to clarify biosimilar safety, efficacy, and interchangeability, stakeholders can foster trust, improve access, and ensure that biosimilars are widely accepted as high-quality, cost-effective alternatives to originator biologics.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Enhancing Adoption of Infused Biosimilars for a Sustainable Future
October 30th 2024An IQVIA report highlights challenges to the sustainability of infused biosimilars in the US, citing rebate walls and reimbursement policies, and proposes key solutions to enhance adoption and benefits for all stakeholders.
Competitive Pricing in Biosimilars: How Adalimumab Could Shape the Industry
Published: October 29th 2024 | Updated: October 29th 2024Sophia Humphreys, PharmD, MHA, BCBBS, of Sutter Health notes that although initial adoption of adalimumab biosimilars remained low in 2023, competitive pricing pressures have already benefited patients and the health care sector.